As a pharmacist, I’d like to share some recent news in the pharmaceutical industry and explain it in simple terms. The World Health Organization (WHO) has been discussing how better flu vaccines could help us. They’re looking into ways to make these vaccines more effective and accessible. Meanwhile, a company called Valneva saw a decrease in sales for their chikungunya vaccine, Ixchiq, due to market restrictions. This vaccine is important for travelers, so it’s a shame to see this setback. On a positive note, the European Commission has approved a higher dose of Novo Nordisk’s weight loss drug, Wegovy. This is great news for those who need this medication. Many pharmaceutical companies are focusing on research and development (R&D) overseas, even as there’s talk about bringing manufacturing back home. Eli Lilly, for instance, is already taking steps to avoid shortages of a type of diabetes and weight loss medication called GLP-1RAs. In other news, European venture capital firms have teamed up to create the European Life Sciences Coalition, aiming to support and invest in new life sciences projects. There’s also some big news in leadership changes: Belén Garijo, the outgoing CEO of Merck KGaA, will be taking over as the CEO of Sanofi, a major vaccine company. The Mexican Government has made a long-term deal with Moderna to boost their vaccine production capabilities. Looking ahead, Gilead expects a 6% increase in sales for their HIV drugs in 2026, while AstraZeneca anticipates higher profits due to strong demand for their cancer drugs, despite global challenges. Stay informed, and as always, feel free to ask me any questions about these developments.